Molecular Imaging

Developing the next generation of cancer Imaging agents and TARGETED therapies

We are interested in the discovery and development of new molecular imaging methods to image tumour metabolism and the downstream effect of targeted therapeutics.

These next-generation molecular imaging techniques are designed to assess the efficacy of novel and preexisting cancer therapeutics and help describe the fundamental biological mechanisms that drive treatment resistance. Harnessing the same molecular-targeted approach, we are creating new theranostics to not only ‘see’ but treat this devastating disease.

News: Congratulations to our Group leader, Tim Witney, who has just been promoted to Professor.

New lab photo! We’re delighted to welcome new PhD student, Rosie Lewis, and Research Assistant, Huda Hammad Rattu, to the group.

Published in Science Translational Medicine, our new paper in collaboration with UCL and Moderna shows that mRNA therapy can successfully treat a rare genetic liver disease found in children. This paper provides new pathophysiological insights, a novel non-invasive tool to assess the disease with positron emission tomography, and a new curative therapy in a preclinical model of inherited metabolic disease, argininosuccinic aciduria.

New Springer Nature book 'Positron Emission Tomography: Methods and Protocols' now out. Edited by Adam Shuhendler and Tim Witney, the book contains 25 cutting-edge protocols that covers radiochemistry, models and validation, and PET technology. The book provides the definitive collection of protocols related to PET research.

We are delighted to announce that Dr Tim Witney will be the founding Editor-in-Chief of a new Nature Series Journal - npj Imaging - a new avenue for all aspects of imaging research. Learn about Tim’s research & vision for the journal in the Journal’s Q&A, and read the Aims & Scope here. We'll cover the breadth of imaging techniques: from subcellular bioimaging to whole-body medical imaging.